Xigris (Eli Lilly & Co)
Xigris (Eli Lilly & Co) Brand names, Xigris (Eli Lilly & Co) Analogs
Xigris (Eli Lilly & Co) Brand Names Mixture
- No information avaliable
Xigris (Eli Lilly & Co) Chemical_Formula
C1786H2779N509O519S29
Xigris (Eli Lilly & Co) RX_link
http://www.rxlist.com/cgi/generic/drotrecogin.htm
Xigris (Eli Lilly & Co) fda sheet
Xigris (Eli Lilly & Co) msds (material safety sheet)
Xigris (Eli Lilly & Co) Synthesis Reference
No information avaliable
Xigris (Eli Lilly & Co) Molecular Weight
55000
Xigris (Eli Lilly & Co) Melting Point
No information avaliable
Xigris (Eli Lilly & Co) H2O Solubility
No information avaliable
Xigris (Eli Lilly & Co) State
Liquid
Xigris (Eli Lilly & Co) LogP
-0.291
Xigris (Eli Lilly & Co) Dosage Forms
Powder for solution
Xigris (Eli Lilly & Co) Indication
For treatment of severe sepsis
Xigris (Eli Lilly & Co) Pharmacology
Activated Protein C exerts an antithrombotic effect by inhibiting (cleaving) Factors Va and VIIIa. In vitro data indicate that Activated Protein C has indirect profibrinolytic activity through its ability to inhibit plasminogen activator inhibitor-1 (PAI-1) and limiting generation of activated thrombin-activatable-fibrinolysis-inhibitor. The net effect is the reduction or elimination of blood clots
Xigris (Eli Lilly & Co) Absorption
No information avaliable
Xigris (Eli Lilly & Co) side effects and Toxicity
No information avaliable
Xigris (Eli Lilly & Co) Patient Information
No information avaliable
Xigris (Eli Lilly & Co) Organisms Affected
Humans and other mammals
